{"organizations": [], "uuid": "b0c8e07b055e6acfbc93a336c9dc9351f3c23439", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "https://fm.cnbc.com/applications/cnbc.com/resources/img/editorial/2014/11/17/102191601-459118916.1910x1000.jpg", "site_section": "", "section_title": "", "url": "https://www.cnbc.com/2018/04/30/allergan-tops-estimates-as-botox-drives-gains.html", "country": "US", "domain_rank": 767, "title": "Allergan tops estimates as Botox drives gains", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-30T03:00:00.000+03:00", "replies_count": 0, "uuid": "b0c8e07b055e6acfbc93a336c9dc9351f3c23439"}, "author": "Jason Alden", "url": "https://www.cnbc.com/2018/04/30/allergan-tops-estimates-as-botox-drives-gains.html", "ord_in_thread": 0, "title": "Allergan tops estimates as Botox drives gains", "locations": [], "entities": {"persons": [{"name": "jason alden", "sentiment": "none"}], "locations": [], "organizations": [{"name": "allergan", "sentiment": "negative"}, {"name": "bloomberg", "sentiment": "none"}, {"name": "allergan botox", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Botox maker Allergan reported a better-than-expected quarterly profit on Monday and raised its full-year forecast for adjusted net income, driven by higher sales of its medical aesthetics products including the blockbuster wrinkle treatment.\nThe company's shares rose about 2.4 percent to $166.70 in premarket trading.\nSales of Botox, its biggest drug by revenue that is also used in treating chronic migraine and overactive bladders, jumped 14.5 percent to $817.3 million in the first quarter.\nThe company's aesthetics unit, which also sells products to remove excess body fat, posted a near 30 percent jump in sales.\nThe Dublin, Ireland-based company has been conducting a strategic review of its business and considering acquisitions and divestitures.\nAllergan backed away from a bid for Shire Plc earlier this month, after confirming reports that it was mulling an offer for the rare-disease specialist.\nThe company managed to grow its revenue despite \"exclusivity challenges\" for older products, Chief Executive officer Brent Saunders said in a statement.\nU.S. Sales of Allergan's eye drug, Restatsis, which is expected to face competition from cheaper drugs, fell 17.2 percent.\nThe company now expects 2018 adjusted earnings of $15.65 to $16.25 per share, slightly above its previous forecast of $15.25 to $16 per share.\nNet loss attributable to shareholders was $332.5 million, or 99 cents per share, compared with $2.63 billion, or $7.86 per share, a year earlier.\nExcluding one-time items, Allergan reported a profit of $3.74 per share, topping analysts' expectations of $3.36, according to Thomson Reuters I/B/E/S.\nTotal revenue rose 2.8 percent to $3.67 billion, topping analysts' average estimate of $3.59 billion.\nCantor Fitzegerald analyst Louise Chen said a beat and raise was widely anticipated by the street since Allergan's setup looked \"conservative heading into the year.\"", "external_links": [], "published": "2018-04-30T03:00:00.000+03:00", "crawled": "2018-04-30T16:25:35.002+03:00", "highlightTitle": ""}